This study is testing a combination of two drugs, momelotinib and luspatercept, for people with myelofibrosis. Myelofibrosis is a bone marrow disorder that causes scarring in the bone marrow, leading to severe anemia and other symptoms. This study is for you if you have primary myelofibrosis or myelofibrosis that developed after polycythemia vera or essential thrombocythemia, and you need regular blood transfusions. You can join whether or not you've taken a JAK inhibitor (another type of medication for myelofibrosis) before. The main goal is to see how many participants no longer need blood transfusions by Week 24. This study plans to enroll 68 participants, but its current status is unclear.

Study design

This is a Phase 2 interventional study, meaning it tests new treatments in a small group of people to see if they are safe and effective. It plans to enroll 68 participants.

What's involved

Momelotinib will be taken by mouth, and luspatercept will be given as an injection under the skin. The study will measure if you need fewer blood transfusions up to Week 24.

Compensation

Not stated in the trial record.

Follow-up

The main goal of the study is measured up to Week 24.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.